A new artificial tear formulation containing arabinogalactan, hyaluronic acid, and trehalose demonstrated high efficacy, tolerability, and patient-reported satisfaction in improving symptoms of dry eye disease (DED) in a real-world, post-marketing study.
The retrospective study, conducted from April 2022 to June 2023, included 96 adults diagnosed with DED due to various conditions. Patients used the eye drops at different dosing schedules and were evaluated at baseline and after 2 to 3 months using a patient-reported questionnaire.
There was a 98% positive response rate, with significant improvements in comfort (39%), itching (16%), redness (13%), tearing (14%), vision (13%), and photophobia (4%). In addition, 61% of participants reported feeling relief for 1 to 2 hours after using the drops.
This study underscores the potential benefits of the new artificial tear as a safe and effective option for managing DED symptoms in a real-world setting.
Reference
Bedei A, Rocha Cabrera P, Oliveira L, et al. Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye. Clin Ophthalmol. 2025;19:83-91. doi: 10.2147/OPTH.S480668. PMID: 39801568; PMCID: PMC11724676.
Related Content
